Loading organizations...
Aktana has raised $21.0M across 1 funding round.
Key people at Aktana.
Aktana has raised $21.0M in total across 1 funding round.
Based in San Francisco, California, Aktana provides an AI-powered software-as-a-service platform that delivers decision support and intelligent customer engagement tools for the global life sciences industry. The company generates approximately $69.1 million in annual revenue and currently employs between 246 and 277 people worldwide. Its proprietary machine learning technology is utilized by over 300,000 commercial and medical professionals across more than 1,000 global deployments to optimize their outreach strategies. Aktana has secured over $100 million in total venture funding from prominent investors including Safar Partners and Leerink Transformation Partners, while serving major pharmaceutical clients such as Sanofi and Novartis. The enterprise was recently acquired by the digital orchestration firm PharmaForceIQ to further integrate its omnichannel marketing capabilities across the healthcare sector. Aktana was founded in 2008 by Derek Choy and a dedicated team of co-founders.
Aktana is a technology company specializing in AI-driven enterprise software solutions for the life sciences industry. It builds advanced AI-powered platforms that enable pharmaceutical and biopharma companies to optimize omnichannel engagement with healthcare providers (HCPs), synchronize commercial strategies in real time, and improve operational efficiency. By delivering personalized, data-driven insights and recommendations, Aktana helps its clients enhance customer interactions, increase sales, and reduce costs, serving over 350 global life sciences brands with more than 1,000 deployments[1][2][3][4].
Founded in 2008 and based in San Francisco, Aktana was originally known as IncentAlign. The company was founded by experts in AI and life sciences who identified the need for smarter, real-time decision support in pharmaceutical commercial operations. Early traction came from successfully integrating AI into field sales and medical teams’ workflows, enabling more effective engagement with healthcare providers. Over time, Aktana evolved its platform to include a proprietary blend of AI and mobile intelligence that closes the loop from strategy inception to field execution, continuously refining commercial and medical engagement[2][3].
Aktana rides the growing trend of AI-powered decision support and omnichannel engagement in the pharmaceutical and life sciences sectors, where personalized, compliant, and data-driven interactions with healthcare providers are increasingly critical. The timing is favorable due to rising complexity in healthcare markets, digital transformation mandates, and the need for real-time strategy adaptation. By enabling biopharma companies to close the gap between strategy and field execution, Aktana influences the broader ecosystem by accelerating AI adoption and improving patient outcomes through smarter commercial and medical engagement[3][4].
Looking ahead, Aktana is positioned to expand its influence by further enhancing its AI capabilities, scaling deployments, and deepening integrations with CRM and data platforms. Emerging trends such as generative AI and increased regulatory scrutiny will shape its product evolution, emphasizing transparency, compliance, and even more personalized engagement. As the life sciences industry continues to embrace digital transformation, Aktana’s role as a leader in intelligent customer engagement is likely to grow, driving measurable impact for clients and contributing to better healthcare delivery worldwide[2][3][4].
Aktana has raised $21.0M in total across 1 funding round.
Aktana's investors include Transformation Capital.
Key people at Aktana.
Aktana has raised $21.0M across 1 funding round. Most recently, it raised $21.0M Series C in September 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2018 | $21M Series C | — | Transformation Capital | Announced |
